Sanofi (SNY) Cash from Operations (2009 - 2026)
Sanofi (SNY) posted Cash from Operations of 3440591087.72 for Q2 2026, up 74.62% sequentially from 1970364929.08 in Q1 2026, and up 107.9% YoY from 1654925063.84 in Q2 2025.
Sanofi (SNY) Cash from Operations (2009 - 2026) Analysis & Trends
Sanofi has reported Cash from Operations for 9 years, with the latest figure at 3440591087.72 in Q2 2026.
- Quarterly Cash from Operations rose 107.9% year-over-year to 3440591087.72 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 25188579550.03 (up 12.2% YoY) and the FY2025 annual result came in at 12513467783.01, up 28.95% from the prior year.
- Cash from Operations climbed to 3440591087.72 in Q2 2026 per SNY's latest filing, from 1970364929.08 in the prior quarter.
- Over five years, Cash from Operations peaked at 11967679607.6 in Q4 2023 and troughed at 95599835.5 in Q1 2024.
- A 5-year average of 5055202431.04 and a median of 3167237041.2 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations slumped 96.76% in 2024, then jumped 2202.93% in 2025.
- Over 5 years, Cash from Operations stood at 11195174339.4 in 2022, then increased by 6.9% to 11967679607.6 in 2023, then fell by 12.22% to 10505361379.0 in 2024, then advanced by 6.97% to 11237676090.9 in 2025, then plunged by 69.38% to 3440591087.72 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 3440591087.72, 1970364929.08, and 11237676090.9 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.44 Bn |
| Jun 30, 2026 | 3.44 Bn |
| Mar 31, 2026 | 1.97 Bn |
| Mar 31, 2026 | 1.97 Bn |
| Dec 31, 2025 | 11.24 Bn |
| Dec 31, 2025 | 11.24 Bn |
| Sep 30, 2025 | 8.54 Bn |
| Sep 30, 2025 | 8.54 Bn |
| Jun 30, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1.65 Bn |
| Mar 31, 2025 | 2.20 Bn |
| Mar 31, 2025 | 2.20 Bn |
| Dec 31, 2024 | 10.51 Bn |
| Dec 31, 2024 | 10.51 Bn |
| Sep 30, 2024 | 8.09 Bn |
| Sep 30, 2024 | 8.09 Bn |
| Jun 30, 2024 | 1.44 Bn |
| Jun 30, 2024 | 1.44 Bn |
| Mar 31, 2024 | 95.60 Mn |
| Mar 31, 2024 | 95.60 Mn |